Format

Send to

Choose Destination
Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1175-1191. doi: 10.1158/1055-9965.EPI-17-0358. Epub 2017 Jun 22.

A Review of Pulmonary Toxicity of Electronic Cigarettes in the Context of Smoking: A Focus on Inflammation.

Author information

1
Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, and College of Medicine, Columbus, Ohio. Peter.Shields@osumc.edu.
2
Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, and College of Public Health, Ohio.
3
Comprehensive Cancer Center, The Ohio State University and James Cancer Hospital, and College of Medicine, Columbus, Ohio.
4
Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York.
5
Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
6
Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
7
Department of Internal Medicine, The Ohio State University, Columbus, Ohio.

Abstract

The use of electronic cigarettes (e-cigs) is increasing rapidly, but their effects on lung toxicity are largely unknown. Smoking is a well-established cause of lung cancer and respiratory disease, in part through inflammation. It is plausible that e-cig use might affect similar inflammatory pathways. E-cigs are used by some smokers as an aid for quitting or smoking reduction, and by never smokers (e.g., adolescents and young adults). The relative effects for impacting disease risk may differ for these groups. Cell culture and experimental animal data indicate that e-cigs have the potential for inducing inflammation, albeit much less than smoking. Human studies show that e-cig use in smokers is associated with substantial reductions in blood or urinary biomarkers of tobacco toxicants when completely switching and somewhat for dual use. However, the extent to which these biomarkers are surrogates for potential lung toxicity remains unclear. The FDA now has regulatory authority over e-cigs and can regulate product and e-liquid design features, such as nicotine content and delivery, voltage, e-liquid formulations, and flavors. All of these factors may impact pulmonary toxicity. This review summarizes current data on pulmonary inflammation related to both smoking and e-cig use, with a focus on human lung biomarkers. Cancer Epidemiol Biomarkers Prev; 26(8); 1175-91. ©2017 AACR.

PMID:
28642230
PMCID:
PMC5614602
DOI:
10.1158/1055-9965.EPI-17-0358
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center